Eli Lilly’s next-generation obesity drug, retatrutide, has shown promising results in rapid weight loss and blood sugar reduction in people with diabetes, according to new data shared at the American Diabetes Association’s annual meeting. However, safety concerns have emerged, as seven participants in a recent study experienced irregular heartbeats and three faced major cardiovascular complications, highlighting the need for careful monitoring of this treatment.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.statnews.com/2026/06/06/illy-retatrutide-triple-g-weight-loss-obesity-safety-data-ada/
